blind randomized placebo

Related by string. * Bed Liner . BLIND . BLIN . Blind : blind placebo controlled . blind eye . Blind Faith . Blind Side / Randomized . randomizing . randomizer : randomized controlled trial . randomized controlled trials . randomized clinical trials . randomized controlled clinical trials / placebos . Placebo . Placebos : placebo controlled clinical trials . randomized placebo controlled . double blind placebo * *

Related by context. All words. (Click for frequent words.) 85 blind randomized 83 double blind placebo 80 randomized double 80 randomized placebo controlled 79 placebo controlled 78 placebo controlled randomized 76 prospective randomized 76 blind placebo controlled 76 Phase III randomized 75 randomized controlled 75 blind randomized controlled 74 prospective randomized placebo 74 double blinded placebo 73 randomized multicenter 73 masked placebo controlled 73 multicenter 73 multicenter randomized double 72 multicenter randomized 72 placebo controlled Phase 72 double blinded randomized 72 blind multicenter 71 multicenter randomized placebo controlled 71 randomized 70 multicentre 70 multicentre randomized double 70 randomized clinical 70 randomized Phase III 69 dose escalation trial 69 blinded placebo controlled 69 prospective randomized controlled 68 dose dose escalation 68 placebo controlled Phase III 68 placebo controlled clinical 68 dose escalation study 67 blind randomized multicenter 67 controlled multicenter 67 prospective multicenter 67 label dose escalation 66 randomized #:# 66 multicenter placebo controlled 66 observer blinded randomized 66 multicentre randomized 66 Phase 1b clinical 66 blinded randomized placebo controlled 66 prospective observational 65 phase IIb 65 Phase 2b study 65 blinded randomized 65 active comparator 65 randomized controlled clinical 65 single ascending dose 65 Phase IIb trial 65 multicenter multinational 65 prospective randomized multicenter 65 Phase Ib 65 TMC# C# 65 dose escalation Phase 64 blind placebo 64 safety tolerability pharmacokinetics 64 label multicenter 64 multicenter prospective 64 pivotal Phase III 64 ascending dose 64 multicenter study 64 Phase 2b 64 multicenter Phase III 64 randomized blinded placebo 64 Phase IIIb 63 Phase 1b trial 63 Randomized 63 prospective multicenter randomized 63 Phase IIb 63 randomized controlled trial 63 randomized blinded 63 multicenter Phase II 63 blind multicentre 63 Phase 2a clinical 63 Phase 2b trial 63 Phase Ib clinical 63 multicenter phase 63 phase IIa 63 phase Ib 63 multiple ascending dose 63 placebo controlled dose escalation 63 ascending doses 62 multicenter clinical 62 Phase 1a 62 phase IIb clinical 62 Phase 2b clinical 62 RG# ITMN 62 LUX Lung 62 RE LY ® 62 multicenter randomized controlled 62 landmark ATHENA 62 Phase III placebo controlled 62 phase IIa clinical 62 Phase III clinical 62 randomized Phase IIb 62 Phase 1b 61 Phase III randomized placebo 61 placebo controlled studies 61 dose cohorts 61 multicenter Phase 61 pharmacokinetics PK 61 randomized multicentre 61 Phase IIa 61 dose regimens 61 PRE SURGE 61 controlled dose escalation 61 Phase IIIb clinical 61 randomized placebo 61 dose escalation 61 pharmacodynamics 61 pivotal Phase 60 randomized Phase 60 Phase IIa trial 60 Phase Ia 60 safety tolerability 60 nonrandomized 60 AIR CF1 60 Phase IIb clinical 60 Phase 2a trial 60 HCV SPRINT 60 multinational multicenter randomized 60 safety tolerability pharmacokinetic 60 mg BID 60 viral kinetic 60 Randomized Double Blind Placebo 60 Randomised 59 phase IIIb 59 Phase Ib II 59 placebo controlled clinical trials 59 TG MV 59 randomized controlled Phase 59 dyskinesia PD LID 59 dosing cohorts 59 BRIM3 59 nab paclitaxel 59 prospective cohort 59 pegylated interferon alfa 2a 59 Phase IIb randomized 59 Multicenter 59 clinical trial 59 Initiated Phase 59 Phase III 59 pharmacodynamic profile 59 EURIDIS 59 NO# [002] 59 Sorafenib HCC Assessment 59 Phase 2a 59 Placebo controlled 59 tolerability 59 ADVANCE PD 59 label multicenter Phase 59 randomized multicenter trial 59 TAXUS ATLAS 59 Phase IIa clinical 58 sunitinib malate 58 ONTARGET 58 placebo controlled trials 58 HCV RESPOND 2 58 RE LY 58 FAME Study 58 mg administered orally 58 prospectively randomized 58 APTIVUS 58 Randomized Double blind 58 phase 2a 58 BRIM2 58 pharmacokinetic PK 58 Phase III pivotal 58 BOLDER II 58 phase IIb study 58 Phase 2b randomized 58 randomized controlled multicenter 58 label dose titration 58 subanalysis 58 Pivotal Trial 58 ROCKET AF 58 REALITY Trial 58 phase IIb trial 58 evaluating tivozanib 57 AIR CF2 57 ritonavir boosted 57 Clinical Antipsychotic Trials 57 label multicenter randomized 57 Randomized Phase 57 Placebo Controlled 57 randomized crossover 57 ACTEMRA TM 57 STEALTH C 57 dosing regimens 57 Val HeFT 57 oral rivaroxaban 57 GetGoal Phase III 57 PRECiSE 57 tolerability pharmacokinetics 57 dose escalation clinical 57 oral deforolimus 57 investigational oral 57 Initiate Phase 57 relapsed MM 57 diabetic neuropathic pain 57 AIR2 Trial 57 treatment naive genotype 57 trials RCTs 57 pharmacokinetics 57 mg dose 57 PEGINTRON TM 57 primary hypercholesterolemia 57 zonisamide SR 57 relapsed refractory multiple myeloma 57 Phase #b/#a 56 teriflunomide 56 PREZISTA r 56 prospectively defined 56 dabigatran etexilate 56 RSD# oral 56 LEXIVA r 56 randomized Phase 2b 56 CTA# Injection 56 nitazoxanide 56 HPTN 56 ZYBRESTAT fosbretabulin 56 TMC# r 56 telaprevir dosing 56 Phase III multicenter 56 dosage regimens 56 relapsed myeloma 56 SPIRIT FIRST 56 BR.# 56 randomized clinical trials 56 bosentan 56 treatment naïve genotype 56 Phase III Clinical Trial 56 CAMMS# 56 phase III ACCLAIM 56 lacosamide 56 Phase #/#a 56 Parkinson disease levodopa induced 56 LibiGel Phase III 56 longitudinal cohort study 56 confirmatory Phase III 56 multicentre study 56 Randomized Evaluation 56 RE SURGE 56 Betaferon ® 56 ExTRACT TIMI 56 IIa clinical 56 Edge STudy 56 Randomized Clinical Trial 56 relapsing remitting multiple sclerosis 56 Phase Ib clinical trials 55 analgesic efficacy 55 PRoFESS 55 #mg/day [001] 55 VICTOR E1 55 REYATAZ r 55 Matrix Phase 2b 55 Adalimumab 55 multicentre prospective 55 MSI #F 55 Multiple Ascending Dose 55 prospective nonrandomized 55 TRANSFORMS 55 PRTX 55 randomized controlled trials 55 dose titration 55 TAXUS V 55 Phase III Clinical Trials 55 ritonavir boosted atazanavir 55 ascending dose study 55 symptomatic BPH 55 Pivotal Phase 55 registrational trial 55 ENESTnd 55 Phase IIIb study 55 Phase 1a clinical 55 metastatic HRPC 55 dose escalation phase 55 tolerated dose MTD 55 multicenter randomized clinical 55 EVEREST II 55 dose placebo controlled 55 Multicenter Randomized Double 55 RG# [001] 55 pharmacokinetic PK study 55 rALLy clinical trial 55 Pegasys ® 55 Phase Ib study 55 oral ridaforolimus 55 mg RDEA# 55 inhalations twice 55 vicriviroc 55 pivotal bioequivalence 55 EDEMA3 55 Double Blind Placebo 55 PRECISE 55 plus ribavirin 55 CLARITY study 55 OLYMPIA registry 55 plus dexamethasone 55 daily Infergen 55 dosing cohort 55 Intervention Effectiveness 55 Traficet EN 55 ANCHOR trial 55 eculizumab 55 evaluating Xcytrin 55 coadministration 55 TAXUS IV 55 Multicentre 55 posaconazole 55 phase Ib clinical 55 ECASS 55 INSPIRE Trial Phase III 55 Denufosol 55 CHAMPION PCI 54 APPRAISE 54 factorial design 54 docetaxel Taxotere R 54 controlled multicenter Phase 54 LITHE 54 prospective multicentre 54 Acute Ischemic Stroke 54 mGluR5 negative 54 MERLIN TIMI 54 Trial Evaluating 54 trastuzumab emtansine T DM1 54 pharmacodynamics PD 54 plus Copegus R 54 Tolvaptan 54 subcutaneously administered 54 mg QD 54 icatibant 54 peginterferon alfa 2b 54 randomized #:#:# 54 dose regimen 54 ISIS # 54 Phase 1b clinical trials 54 randomized trials 54 Pivotal Phase III 54 confirmatory clinical 54 COMFORT II 54 REVLIMID lenalidomide 54 alvespimycin 54 AIR CF3 54 VIRAMUNE XR 54 Phase III randomized controlled 54 DU #b 54 administered subcutaneously 54 pertuzumab 54 adjunctive placebo 54 NCCTG 54 darunavir ritonavir 54 docetaxel chemotherapy 54 randomized multicenter Phase III 54 CLL8 54 APEX PD 54 pramlintide 54 PREVAIL 54 DAPT 54 EQUIP OB 54 GAMMAGARD 54 DSMB 54 riociguat 54 boosted protease inhibitor 54 Efficacy 54 dosing schedules 54 Dose Ranging Study 54 MEND CABG 54 Microplasmin 54 CRx 54 Controlled Study 54 azacitidine 54 Phase IIB 54 PREZISTA ritonavir 54 afatinib 54 sorafenib Nexavar ® 54 Prostate Lung Colorectal 54 Study Evaluating 54 forodesine 54 PSN# [002] 54 INCB# [001] 54 Myocardial Infarction Study 54 ACTEMRA 54 clinical pharmacology studies 54 mg doses 54 Amrubicin 54 bevirimat Study 54 opioid induced bowel dysfunction 54 beta2 agonist 54 ToGA 54 desvenlafaxine succinate 54 Carotid Revascularization Endarterectomy vs. 54 multicentre randomized controlled 54 mcg kg 54 alfa 2a 54 IFN alfa 54 pegylated interferon alfa 2b 54 maximally tolerated dose 54 Navelbine 54 fluticasone furoate 54 brivaracetam 54 APTIVUS r 54 By JENNIFER LEARN 54 ongoing Phase 1b 54 dose pharmacokinetic 54 blinded placebo 54 Randomized Controlled 54 peginterferon alfa 2a 54 Trandolapril 54 comparing alemtuzumab 54 dose cohort 54 interferon beta 1b 54 ALLEGRO 54 TMC# [001] 54 Prospective Randomized 54 refractory CLL 54 FREEDOMS 54 pharmacokinetic studies 54 MIVI III 54 ABSORB clinical 54 Phase Ib IIa 54 #:# randomization 54 Phase IIb trials 54 SPIRIT IV 54 HGS# 54 hour bronchodilation 54 EMPHASIS HF trial 54 observational study 54 evaluable patients 54 II Clinical Trial 54 pharmacokinetic profile 54 PFO migraine 54 rapid virologic response 54 Phase III clinical trials 53 OPT CHF 53 ABSORB trial 53 EchoCRT 53 pimecrolimus cream 53 Controlled Trial 53 non inferiority 53 #mg dose [001] 53 Phase III trials 53 Phase III Pivotal 53 monotherapy 53 AZILECT R 53 Phase III confirmatory 53 μg dose 53 mg/m2 dose 53 null responder HCV 53 SCH # 53 ENDEAVOR II 53 Teriflunomide 53 Study ADX# 53 GOUT 53 mg TID 53 RESOLUTE 53 irbesartan 53 pharmacokinetic 53 comparing XIENCE V 53 comparator arm 53 NATRECOR ® 53 antiretroviral naive 53 substudy 53 unblinded 53 weekly subcutaneous injections 53 IV bolus 53 subcutaneous formulation 53 genotype 1a 53 Blind Placebo Controlled 53 CANCIDAS 53 FOLOTYN ® 53 observational cohort study 53 risperidone Risperdal 53 randomized discontinuation trial 53 registrational Phase 53 Zenvia ™ 53 International Verapamil SR 53 placebo controlled multicenter 53 fosbretabulin 53 REYATAZ ritonavir 53 CONQUER OB 53 AEGR 53 Board DSMB 53 EXPAREL TM 53 relapsing multiple sclerosis 53 Laquinimod 53 CALGB 53 CIMZIA TM certolizumab pegol 53 #mg QD [002] 53 DAPT Study 53 prucalopride 53 Left Ventricular Dysfunction 53 Ophena TM 53 oral prodrug 53 rosuvastatin 53 colesevelam HCl 53 Phase IIa trials 53 ORMD 53 elotuzumab 53 DLTs 53 CUSTOM II 53 secondary efficacy endpoints 53 metreleptin 53 CIMZIA TM 53 evaluating Vectibix 53 Intervention Trial 53 Phase III ThermoDox 53 adalimumab 53 Tyrima 53 davunetide intranasal AL 53 telaprevir dosed 53 PEGASYS ® 53 TELCYTA 53 SEROQUEL 53 RezularTM 53 AVOREN 53 tanespimycin 53 Sapacitabine 53 ACTIVE W 53 LCP AtorFen 53 paclitaxel poliglumex 53 receptor tyrosine kinase inhibitor 53 3TC lamivudine Epivir 53 Randomized controlled 53 AIM HIGH 53 REVIVE Diabetes 53 pharmacodynamic effects 53 RIBBON 53 candesartan cilexetil 53 8mg/kg 53 insulin detemir 53 Dacogen injection 53 huC# DM4 53 cetrorelix 53 Phase IIb III 53 teduglutide 53 telmisartan 53 Prostate AdenoCarcinoma Treatment 53 #mg/m# [002] 53 Phase 1b dose escalation 53 recurrent malignant glioma 52 IL# PE#QQR 52 thorough QT 52 painful diabetic neuropathy 52 GEM OS1 52 landmark ATHENA study 52 Phase III metastatic melanoma 52 EFAPROXYN 52 lubiprostone 52 assessing T DM1 52 galiximab 52 tocilizumab 52 Cardiac Allograft Rejection 52 prospective observational cohort 52 subcutaneous doses 52 BOLDER 52 MAGE A3 ASCI 52 CRESTOR #mg 52 CA4P 52 NSABP B 52 pharmacokinetic PK profile 52 Blinatumomab 52 Blind Placebo Controlled Trial 52 CORD II 52 intravenous dose 52 Ranolazine 52 recurrent glioblastoma multiforme 52 Testosterone MDTS ® 52 ABC/3TC 52 hyperphenylalaninemia HPA due 52 evaluable subjects 52 TRITON TIMI 52 edoxaban 52 KRN# 52 PROMACTA 52 RLAI 52 Ozarelix 52 DURATION 52 dacarbazine 52 Augment Injectable 52 registrational 52 ARDIS 52 Omacetaxine mepesuccinate 52 confirmatory Phase 3 52 6R BH4 52 Prostate Cancer Prevention 52 plus gemcitabine 52 PRX # 52 thymalfasin 52 budesonide foam 52 sorafenib Nexavar 52 LUMINATE 52 Taxotere ® 52 NRTI 52 Phase IIA 52 tacrolimus ointment 52 R#/MEM # 52 SPIRIT III 52 4mg/kg 52 QD dosing 52 visilizumab 52 AVADO 52 Metabolic Efficiency 52 evaluating REVLIMID 52 Zenvia Phase III 52 Intervention Trial GAIT 52 Tiotropium 52 TAXUS VI 52 Diabetic Macular Edema 52 refractory NSCLC 52 bolus injection 52 #mg BID [001] 52 Randomized Double Blind 52 Sym# 52 neratinib 52 Raloxifene Evaluation MORE 52 RIO Lipids 52 ARIXTRA 52 ofatumumab 52 ADAGIO study 52 receiving INTRON 52 plus prednisone 52 de novo kidney transplant 52 primary endpoint 52 fenofibric acid 52 angiotensin receptor blocker ARB 52 NATRECOR R 52 investigational protease inhibitor 52 ENDEAVOR IV 52 events SAEs 52 HCD# [002] 52 CATIE AD 52 q8h 52 mixed dyslipidemia 52 DIRECT Trial 52 cell lymphoma CTCL 52 bicifadine 52 Placebo Controlled Trial 52 Phase IIb Trial 52 ZACTIMA 52 MADIT II 52 bendamustine 52 IMPACT IMmunotherapy 52 phase IIb III 52 MabCampath 52 JANUVIA 52 events AEs 52 PRADAXA 52 Randomized Placebo Controlled 52 ASCEND HF 52 dosing 52 VITAL Trial 52 Clonicel 52 FOLFOX 52 perampanel 52 intravitreal injection 52 acute coronary syndromes ACS 52 serotonin norepinephrine reuptake inhibitor 52 Pharmacokinetic 52 Phase III Trial 52 Copegus ® ribavirin 52 selective androgen receptor modulator 52 SUCCEED trial 52 retrospective cohort 52 RRMS patients 52 COU AA 52 CRLX# 52 Cloretazine 52 tolvaptan 52 sunitinib 52 subcutaneous SC 52 satraplatin Phase 52 aripiprazole Abilify 52 miconazole Lauriad ® 52 ziprasidone Geodon 52 ISENTRESS 52 Clinical Study 52 Phase III VISTA 52 Neulasta R 52 Diabetic Macular Edema DME 52 ZD# [001] 52 HGS ETR1 52 ABCSG 52 FASLODEX 52 XIENCE V Stent System 52 liposome injection 52 MEND CABG II 52 virus HCV protease inhibitor 52 INCB# [003] 52 antiepileptic drug 52 latrepirdine 52 Ambulatory Blood Pressure 52 Platelet Inhibition 52 investigational compound 52 eosinophilic asthma 52 DASISION 52 TTF Therapy 52 Lodotra TM 52 RECORD1 52 EINSTEIN DVT 52 dexpramipexole 52 Monotherapy 52 BCIRG 52 randomized controlled clinical trials 52 PEG INTRON R 52 etanercept 52 low dose cytarabine 52 Oral Fingolimod 52 pain palliation 51 lorcaserin Phase 51 mixed hyperlipidemia 51 Combination REOLYSIN R 51 Safinamide 51 fostamatinib 51 R# #mg BID 51 pharmacokinetic pharmacodynamic 51 celgosivir 51 q#h 51 PCI ExTRACT TIMI 51 subgroup analyzes 51 AEG# 51 dose limiting toxicities 51 pegylated interferon 51 baminercept 51 CURRENT OASIS 7 51 Degarelix 51 Stenting Trial CREST 51 ACCOMPLISH 51 protease inhibitor PI 51 Meets Primary Endpoint 51 unique alkylating agent 51 reslizumab 51 efavirenz EFV 51 SUTENT 51 glatiramer acetate 51 fluvastatin 51 venlafaxine XR 51 lexidronam injection 51 NOXAFIL Oral Suspension 51 #mg dose [003] 51 oxycodone CR 51 intermittent dosing 51 IIa clinical trial 51 ID NCT# 51 retrospective cohort study 51 Phase IIb IIIa 51 DermaVir Patch 51 multicenter dose escalation 51 axitinib 51 pharmacodynamic 51 PROPEL 51 PEG PAL 51 BENICAR HCT 51 composite endpoint 51 FOLPI 51 HCV infected 51 RDEA# 51 JAK inhibitor 51 evaluating Actimmune 51 VADT 51 non valvular atrial 51 lomitapide 51 evaluating nimotuzumab 51 TLK# 51 AZOR 51 biliary tract cancer 51 docetaxel Taxotere ® 51 mGluR5 NAM 51 noninferiority 51 Eluting Stent 51 acyclovir Lauriad R 51 median PFS 51 HOPE TOO 51 Pegasys R 51 naltrexone SR 51 iniparib 51 GSK# [001] 51 dasatinib Sprycel ® 51 olanzapine Zyprexa 51 Quinamed 51 aplindore 51 bepotastine besilate nasal spray 51 Golimumab 51 virologic 51 TO AVOID PREGNANCY WHILE 51 mcg QD 51 phase III SIMPADICO 51 lopinavir r 51 Locteron ® 51 NEVO 51 viral kinetics 51 ganetespib 51 SYMMETRY trial 51 IMPACT DCM 51 number NCT# ClinicalTrials.gov 51 REVIVE 51 Phase III ALLEGRO 51 lixisenatide 51 designated HVTN 51 Tocilizumab 51 TMC# [002] 51 ancrod 51 Afatinib 51 metformin sulfonylurea 51 mg/m2 51 SYNTAX trial 51 ribavirin RBV 51 CCX# B 51 CR# vcMMAE 51 European Sepsis Trial 51 pitavastatin 51 glufosfamide 51 dextromethorphan quinidine 51 Empatic 51 trials BLISS 51 interferon gamma 1b 51 lopinavir r arm 51 Polyp Prevention Trial 51 Betaferon R 51 Engerix B 51 FOLFIRI 51 HGS ETR2 51 Randomized Phase II 51 EVIZON 51 mapatumumab 51 Methylnaltrexone 51 superficial bladder cancer 51 unblinding 51 blinded randomized controlled 51 Pegasys plus Copegus 51 dirucotide MBP# 51 EGFR HER2 51 fallopian tube cancers 51 selective phosphodiesterase 51 MIRCERA 51 KAPIDEX 51 ritonavir boosted danoprevir 51 Double Blind Randomized 51 Endovascular Valve Edge 51 Pharmacokinetic Study 51 aliskiren 51 ORENCIA ® 51 Elagolix 51 ORACLE MS 51 Phase 2b kidney transplant 51 eltrombopag 51 allosteric modulator NAM 51 EOquin TM 51 Phase #b/#a clinical 51 heFH 51 Peg IFN 51 basal bolus regimen 51 bile duct tumor 51 Fibrin Pad 51 Carfilzomib 51 Efficacy Results 51 albinterferon alfa 2b 51 intravenous doses 51 CERVARIX 51 Clinical Trial Evaluating 51 sulodexide 51 tolerability profile 51 BENICAR 51 unfractionated heparin UFH 51 eszopiclone 51 refractory gout 51 Enzastaurin 51 daunorubicin 51 relapsed APL 51 TYKERB 51 Aplidin R 51 CRVO 51 pregabalin Lyrica 51 generalized anxiety disorder GAD 51 n = 51 subcutaneous dose 51 recurrent GBM 51 laquinimod 51 ceftazidime 51 pralatrexate injection 51 ofatumumab HuMax CD# 51 Cloretazine R VNP#M 51 IIIa inhibitor 51 Proellex TM 51 liposomal formulation 51 glycopyrrolate 51 #mg dosing 51 Pharmacokinetics PK 51 Tarceva TM 51 e HEALING 51 Wisconsin Sleep Cohort 51 evaluating MGCD# [002] 51 invasive candidiasis 51 HBeAg positive 51 Screening Trial 51 ruboxistaurin 51 varespladib 51 Multicenter Phase 51 HCV NS5B polymerase 51 efficacy tolerability 51 PEG Intron ® 51 BARI 2D 51 NOXAFIL 51 mcg doses 51 ENGAGE AF TIMI 51 somatostatin analog 51 CARE HF 51 Phase II 51 mcg dose 51 Omacetaxine 51 ALN VSP Phase 51 RADIANT 51 Multi Ethnic Study 51 IIa trials 51 opioid naive 51 investigational pan BCR 51 cilengitide 51 NGX# 51 RELOVAIR ™ 51 ATACAND 51 deferiprone 51 Systemic Sclerosis 51 multicenter randomized Phase 51 Phase 2b clinical trials 51 mg subcutaneous injection 51 refractory metastatic colorectal cancer 51 atypical antipsychotic 50 Cholesterol Levels SPARCL 50 prostate cancer HRPC 50 estramustine 50 Pivotal Study 50 EQUATE OB 50 inhibitor RG# 50 paclitaxel eluting stents 50 YERVOY 50 PRIMO CABG 50 EXPLORE Xa 50 REMINYL ® 50 GW# [003] 50 sequential dose escalation 50 tiotropium 50 PERSEUS 50 aripiprazole 50 Ovarian Cancer Screening 50 REVIVE TA 50 INTEGRILIN R 50 pharmacodynamic profiles 50 #mg/m# [001] 50 Pooled Analysis 50 dosing intervals 50 ELONVA 50 Phenoptin 50 continuous intravenous infusion 50 mg kg dose 50 atorvastatin Lipitor 50 virological failure 50 BAY #-# 50 mg q8h 50 pomalidomide 50 Heart Failure Trial 50 headache nasopharyngitis 50 HeFH 50 Valsartan 50 velafermin 50 CYT# 50 PreCISe 50 carboplatin paclitaxel 50 PD LID 50 mertansine 50 eptifibatide 50 mg/m2 cohort 50 sNDA submission 50 PROTEGE 50 bupropion SR 50 IBS C 50 acute PAO 50 intravenous dosing 50 CIMZIA ™ 50 evaluating carfilzomib 50 STRIDE PD 50 Neovascular AMD 50 capecitabine Xeloda R 50 safinamide 50 Tekturna HCT 50 recurrent glioma 50 MIST II 50 Oral NKTR 50 Phase 2b Clinical Trial 50 Val MARC 50 trabedersen 50 acute mania 50 pharmacodynamic PD 50 Prospective Randomized Trial 50 macrovascular 50 SYMBICORT 50 stable angina pectoris

Back to home page